Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.
Sharmin Ghaznavi, Sarah G Richter
Drugs May 1, 2025 DOI: 10.1007/s40265-025-02172-2 via PubMed
Summary
AI-generated from the abstractRecent research has revived interest in psychedelics as treatments for depression. This review examines studies on psilocybin, ayahuasca, DMT, and 5-Me-O DMT for treatment-resistant and major depression. It discusses the potential to expand depression treatment options based on available data, while also highlighting the difficulties and limitations of psychedelic research that complicate assessment of that potential.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Psilocybin Ayahuasca Dimethyltryptamine (DMT) |
| Keywords | Mental health Depression treatment Clinical research Therapeutic breakthroughs Psychedelics |
| Citations | 6 |
| Key finding | Psychedelics show potential as treatments for depression, but research limitations make assessing that potential challenging. |
Abstract
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding treatment options for depression based on the data available, as well as the difficulties and limitations of research on psychedelics that make assessing that potential more challenging.